23andMe was once worth $6 billion. What's left of the DNA testing startup is being bought for $256 million.

Core Insights - Regeneron Pharmaceuticals is acquiring the assets of 23andMe for $256 million, which includes its personal genome service, total health, research services, and biobank of genetic samples [1] - 23andMe will continue to provide consumer genome services post-acquisition [1] Group 1: Acquisition Details - The acquisition aims to enhance 23andMe's mission of helping individuals understand their DNA and improve personal health, while also supporting Regeneron's genetic research initiatives [2] - The deal is expected to close in the third quarter of this year, with Regeneron required to adhere to 23andMe's privacy policies regarding customer data [3] Group 2: Company Background - 23andMe filed for Chapter 11 bankruptcy protection in March, leading to the immediate resignation of CEO Anne Wojcicki [4] - The company, which went public in 2021 with a valuation of $6 billion, has struggled to achieve profitability and faced significant challenges, including a $30 million settlement for a data breach and substantial layoffs [5] - As of November, 23andMe reported debts of $2.3 billion and approximately $126 million in cash and cash equivalents, indicating a need for additional liquidity [5]